Spero Therapeutics (NASDAQ:SPRO) Announces Quarterly Earnings Results

Spero Therapeutics (NASDAQ:SPRO) issued its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, FiscalAI reports. The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.26 million. Spero Therapeutics had a return on equity of 38.62% and a net margin of 24.90%.

Spero Therapeutics Trading Down 0.2%

NASDAQ SPRO traded down $0.01 during midday trading on Friday, hitting $2.76. The company had a trading volume of 722,231 shares, compared to its average volume of 381,698. The company has a market capitalization of $159.51 million, a PE ratio of 11.48 and a beta of 1.43. The firm has a 50-day moving average price of $2.55 and a 200-day moving average price of $2.42. Spero Therapeutics has a twelve month low of $0.63 and a twelve month high of $3.22.

Insider Activity

In related news, insider Esther Rajavelu sold 25,240 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $2.51, for a total value of $63,352.40. Following the transaction, the insider owned 986,851 shares in the company, valued at approximately $2,476,996.01. This trade represents a 2.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Spero Therapeutics

Several hedge funds have recently bought and sold shares of the company. GSK plc acquired a new position in shares of Spero Therapeutics in the 4th quarter valued at approximately $21,414,000. Vanguard Group Inc. boosted its position in shares of Spero Therapeutics by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock worth $3,741,000 after acquiring an additional 39,474 shares in the last quarter. State Street Corp increased its stake in Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after acquiring an additional 19,200 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Spero Therapeutics during the fourth quarter valued at approximately $306,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Spero Therapeutics during the third quarter valued at approximately $283,000. 25.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on SPRO shares. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Sunday, March 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce”.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.